Can you actually use my 23andMe raw data?

Yes, we can use your 23andMe raw data. We run it through clinical-grade analysis tools that look at variants beyond the consumer-facing 23andMe report. Raw data covers about 600,000 SNPs, which is enough for many pharmacogenomic and pathway questions, but it does not replace whole genome sequencing for rare-variant detection.

What is the difference between consumer and clinical genetic testing?

The difference between consumer and clinical genetic testing is depth, accuracy, and regulation. Consumer tests like 23andMe screen common variants and are FDA-cleared for limited uses. Clinical tests like Invitae or Color use validated CLIA labs and report on medically actionable variants with much higher confidence.

Do I need a referral to upload my data?

You do not need a referral to upload your data if you are already a Fishtown Medicine patient. Just attach the raw file in the Ultralight app. If you are not a member yet, schedule an intro visit and we will set up the secure upload during onboarding.

Will my genetic data be shared with insurance?

Your genetic data will not be shared with insurance from our office. Your records are protected by HIPAA. The federal GINA law also prohibits health insurers and employers from discriminating based on genetic information. Note that GINA does not cover life insurance, disability insurance, or long-term care insurance.

How long does the review take?

The review takes 7 to 10 days from upload to consult. We need time to process the raw data, cross-reference variants against current literature, and prepare the pathway summary. Rushing the review usually means missing the most useful insights.

Is whole genome sequencing better than 23andMe?

Whole genome sequencing is better than 23andMe for depth and rare-variant detection. WGS covers 100% of your DNA. 23andMe covers about 0.02%. For most healthy adults, 23andMe data is enough to start. For complex family histories or unexplained symptoms, WGS is worth the cost.

What can pharmacogenomic testing tell me?

Pharmacogenomic testing can tell you how your liver metabolizes specific drug families, including SSRIs, opioids, beta-blockers, statins, and PPIs. It can prevent years of trial and error with antidepressants and reduce the risk of overdose with codeine in ultra-rapid metabolizers.

Will the consult tell me if I have cancer genes?

The consult will tell you if your data shows known cancer-risk variants like BRCA1, BRCA2, or Lynch syndrome genes. Consumer raw data only flags some of these. We often recommend a confirmatory clinical panel (Invitae) before any major decision based on a 23andMe result alone.

What is a polygenic risk score and how do you use it?

A polygenic risk score (PRS) combines many small genetic variants into one number that estimates your inherited risk for a specific disease. We use PRS for coronary artery disease, breast cancer, colon cancer, type 2 diabetes, and Alzheimer's, layered on top of family history and lifestyle to refine screening and prevention plans.

How does APOE genotype change cardiovascular and dementia care?

APOE genotype changes care because APOE4 carriers face higher risk of both Alzheimer's disease and cardiovascular disease, and their risk is amplified by saturated fat and alcohol. We are stricter about ApoB targets, sleep quality, exercise, and metabolic markers in APOE4 carriers, and we monitor cognition more carefully starting in midlife.

What is the role of MTHFR variants in real clinical care?

The role of MTHFR variants in real clinical care is more nuanced than the internet suggests. The C677T and A1298C variants slightly reduce folate metabolism efficiency. We do not "treat" MTHFR. We sometimes choose methylfolate over folic acid, particularly in patients with low B12 or B9 status, and we monitor homocysteine.

How do you handle the COMT "warrior vs. worrier" gene?

We handle the COMT gene by using it as a context clue, not a label. Slow-COMT carriers often have higher dopamine baseline, more focus, and more sensitivity to caffeine and stress. We adjust supplements (more magnesium, fewer methyl donors) and conversation about caffeine timing rather than prescribing a specific protocol from a single gene.

What is the difference between BRCA testing and a polygenic breast cancer risk score?

The difference between BRCA testing and a polygenic breast cancer risk score is the type of risk. BRCA1 and BRCA2 are high-penetrance variants that confer 50 to 80% lifetime risk. Polygenic scores combine many small-effect variants and identify the 1 to 2% of women with elevated risk despite being BRCA-negative.

How does pharmacogenomics affect SSRI selection?

Pharmacogenomics affects SSRI selection because CYP2D6 and CYP2C19 status changes how fast you metabolize each drug. Poor metabolizers may build up high levels at standard doses. Ultra-rapid metabolizers may never reach therapeutic levels. We use the data to choose the right drug at the right dose on the first try.

What is GINA and what does it protect?

GINA is the Genetic Information Nondiscrimination Act of 2008. It protects you from discrimination by health insurers and employers based on genetic information. It does not protect you in the markets for life insurance, disability insurance, or long-term care insurance. We discuss this trade-off before any deep genetic testing.

How do you interpret a "variant of uncertain significance" (VUS)?

We interpret a variant of uncertain significance (VUS) by usually doing nothing dramatic. A VUS is a genetic change with no clear medical meaning yet. We document it, follow updates from clinical databases like ClinVar, and re-evaluate periodically. We never let a VUS drive surgery or intensive treatment.

Can lifestyle change override a high-risk genetic profile?

Lifestyle change can substantially override a high-risk genetic profile in many cases. For coronary artery disease, exercise, diet, and lipid lowering can reduce risk by more than 50% even in high-PRS patients. For BRCA1, lifestyle helps but does not replace targeted screening or risk-reducing surgery decisions.

How does Fishtown Medicine handle direct-to-consumer pharmacogenomic kits?

Fishtown Medicine handles direct-to-consumer pharmacogenomic kits cautiously. Some, like GeneSight, are FDA-cleared for psychiatric medications. Others have variable evidence. We treat consumer reports as starting points, confirm with clinical-grade testing when needed, and make decisions based on the totality of clinical context.

What is the future of polygenic embryo screening?

Polygenic embryo screening is an emerging area where IVF embryos are scored for adult disease risk and intelligence proxies. We do not currently use it. The science is early, the ethics are complicated, and the predictive power for any individual embryo is small. We will revisit when the data is stronger.

Why does Fishtown Medicine still emphasize family history alongside genetics?

Fishtown Medicine still emphasizes family history alongside genetics because family history captures shared environment, lifestyle, and genetic variants we have not yet sequenced. A patient whose father and grandfather both died of heart attacks at 50 has meaningful risk even when the 23andMe report looks normal.

Can you actually use my 23andMe raw data?

Yes, we can use your 23andMe raw data. We run it through clinical-grade analysis tools that look at variants beyond the consumer-facing 23andMe report. Raw data covers about 600,000 SNPs, which is enough for many pharmacogenomic and pathway questions, but it does not replace whole genome sequencing for rare-variant detection.

What is the difference between consumer and clinical genetic testing?

The difference between consumer and clinical genetic testing is depth, accuracy, and regulation. Consumer tests like 23andMe screen common variants and are FDA-cleared for limited uses. Clinical tests like Invitae or Color use validated CLIA labs and report on medically actionable variants with much higher confidence.

Do I need a referral to upload my data?

You do not need a referral to upload your data if you are already a Fishtown Medicine patient. Just attach the raw file in the Ultralight app. If you are not a member yet, schedule an intro visit and we will set up the secure upload during onboarding.

Will my genetic data be shared with insurance?

Your genetic data will not be shared with insurance from our office. Your records are protected by HIPAA. The federal GINA law also prohibits health insurers and employers from discriminating based on genetic information. Note that GINA does not cover life insurance, disability insurance, or long-term care insurance.

How long does the review take?

The review takes 7 to 10 days from upload to consult. We need time to process the raw data, cross-reference variants against current literature, and prepare the pathway summary. Rushing the review usually means missing the most useful insights.

Is whole genome sequencing better than 23andMe?

Whole genome sequencing is better than 23andMe for depth and rare-variant detection. WGS covers 100% of your DNA. 23andMe covers about 0.02%. For most healthy adults, 23andMe data is enough to start. For complex family histories or unexplained symptoms, WGS is worth the cost.

What can pharmacogenomic testing tell me?

Pharmacogenomic testing can tell you how your liver metabolizes specific drug families, including SSRIs, opioids, beta-blockers, statins, and PPIs. It can prevent years of trial and error with antidepressants and reduce the risk of overdose with codeine in ultra-rapid metabolizers.

Will the consult tell me if I have cancer genes?

The consult will tell you if your data shows known cancer-risk variants like BRCA1, BRCA2, or Lynch syndrome genes. Consumer raw data only flags some of these. We often recommend a confirmatory clinical panel (Invitae) before any major decision based on a 23andMe result alone.

What is a polygenic risk score and how do you use it?

A polygenic risk score (PRS) combines many small genetic variants into one number that estimates your inherited risk for a specific disease. We use PRS for coronary artery disease, breast cancer, colon cancer, type 2 diabetes, and Alzheimer's, layered on top of family history and lifestyle to refine screening and prevention plans.

How does APOE genotype change cardiovascular and dementia care?

APOE genotype changes care because APOE4 carriers face higher risk of both Alzheimer's disease and cardiovascular disease, and their risk is amplified by saturated fat and alcohol. We are stricter about ApoB targets, sleep quality, exercise, and metabolic markers in APOE4 carriers, and we monitor cognition more carefully starting in midlife.

What is the role of MTHFR variants in real clinical care?

The role of MTHFR variants in real clinical care is more nuanced than the internet suggests. The C677T and A1298C variants slightly reduce folate metabolism efficiency. We do not "treat" MTHFR. We sometimes choose methylfolate over folic acid, particularly in patients with low B12 or B9 status, and we monitor homocysteine.

How do you handle the COMT "warrior vs. worrier" gene?

We handle the COMT gene by using it as a context clue, not a label. Slow-COMT carriers often have higher dopamine baseline, more focus, and more sensitivity to caffeine and stress. We adjust supplements (more magnesium, fewer methyl donors) and conversation about caffeine timing rather than prescribing a specific protocol from a single gene.

What is the difference between BRCA testing and a polygenic breast cancer risk score?

The difference between BRCA testing and a polygenic breast cancer risk score is the type of risk. BRCA1 and BRCA2 are high-penetrance variants that confer 50 to 80% lifetime risk. Polygenic scores combine many small-effect variants and identify the 1 to 2% of women with elevated risk despite being BRCA-negative.

How does pharmacogenomics affect SSRI selection?

Pharmacogenomics affects SSRI selection because CYP2D6 and CYP2C19 status changes how fast you metabolize each drug. Poor metabolizers may build up high levels at standard doses. Ultra-rapid metabolizers may never reach therapeutic levels. We use the data to choose the right drug at the right dose on the first try.

What is GINA and what does it protect?

GINA is the Genetic Information Nondiscrimination Act of 2008. It protects you from discrimination by health insurers and employers based on genetic information. It does not protect you in the markets for life insurance, disability insurance, or long-term care insurance. We discuss this trade-off before any deep genetic testing.

How do you interpret a "variant of uncertain significance" (VUS)?

We interpret a variant of uncertain significance (VUS) by usually doing nothing dramatic. A VUS is a genetic change with no clear medical meaning yet. We document it, follow updates from clinical databases like ClinVar, and re-evaluate periodically. We never let a VUS drive surgery or intensive treatment.

Can lifestyle change override a high-risk genetic profile?

Lifestyle change can substantially override a high-risk genetic profile in many cases. For coronary artery disease, exercise, diet, and lipid lowering can reduce risk by more than 50% even in high-PRS patients. For BRCA1, lifestyle helps but does not replace targeted screening or risk-reducing surgery decisions.

How does Fishtown Medicine handle direct-to-consumer pharmacogenomic kits?

Fishtown Medicine handles direct-to-consumer pharmacogenomic kits cautiously. Some, like GeneSight, are FDA-cleared for psychiatric medications. Others have variable evidence. We treat consumer reports as starting points, confirm with clinical-grade testing when needed, and make decisions based on the totality of clinical context.

What is the future of polygenic embryo screening?

Polygenic embryo screening is an emerging area where IVF embryos are scored for adult disease risk and intelligence proxies. We do not currently use it. The science is early, the ethics are complicated, and the predictive power for any individual embryo is small. We will revisit when the data is stronger.

Why does Fishtown Medicine still emphasize family history alongside genetics?

Fishtown Medicine still emphasizes family history alongside genetics because family history captures shared environment, lifestyle, and genetic variants we have not yet sequenced. A patient whose father and grandfather both died of heart attacks at 50 has meaningful risk even when the 23andMe report looks normal.

How We Review Genetic Results | Fishtown Medicine

TL;DR30-second take

We review genetic data from consumer panels (23andMe, Ancestry) and clinical panels (Invitae, Color, Nucleus) by translating raw variants into pathway-based action: nutrient needs, drug metabolism, cardiovascular risk, and earlier screening timelines. The goal is precision strategy, not labels. Genetics sets the predisposition. Lifestyle decides the outcome.

Your genetics are the blueprint of your health, not your destiny. At Fishtown Medicine, we take your raw data from consumer companies like 23andMe or Ancestry, or from clinical panels like Invitae, Color, or Nucleus, and translate them into a high-leverage personalized care plan.

We do not just look for "bad genes." We look for opportunities to optimize nutrition, medication choice, screening timelines, and lifestyle around your unique biology.

What kind of genetic data can you send us?

You can send us several kinds of genetic data, and we can work with most of them:

Raw DNA data: If you have used 23andMe or Ancestry, you can download your raw .txt file and we run it through clinical-grade analysis tools.
Clinical panels: Reports from companies like Invitae or Color used for cancer screening or familial hypercholesterolemia.
Whole genome sequencing: A 30x WGS report from Nucleus or Nebula covers 100% of your DNA.
Specialized panels: Pharmacogenomic tests, MTHFR-specific reports, APOE status, and BRCA testing.

How to share: Upload files directly to your secure portal in the Ultralight app. We never email genetic data.

What is our interpretation framework?

Our interpretation framework uses pathway analysis instead of single-gene labeling. We do not crown you "the MTHFR patient" or "the APOE4 patient." We ask: where does your biology need extra support?

Metabolic pathway: Genetic tendencies toward insulin resistance, high triglycerides, or fatty liver.
Detoxification pathway: How well your body handles oxidative stress, alcohol, and environmental exposures.
Cardiovascular pathway: Markers like Lp(a) and familial hypercholesterolemia variants that standard labs often miss.
Longevity pathway: APOE status, polygenic risk scores for neurodegeneration, and protective strategies you can deploy today.
Pharmacogenomics: How fast or slow you metabolize specific drug families (CYP2D6, CYP2C19, CYP3A4).

How does genetics change your care plan?

Genetics changes your care plan by replacing generalized advice with precision action. A few real examples:

Nutrient precision: A specific MTHFR variant may push us to use methylated B-vitamins instead of standard ones.
Medication safety: CYP2D6 status changes the safe dose of antidepressants, opioids, and beta-blockers.
Screening timelines: A high polygenic risk score for breast or colon cancer can move your preventive imaging timelines up by a decade.
Cardiovascular targets: APOE4 carriers often need stricter ApoB and saturated-fat targets, since the gene amplifies risk from both.
Hormone strategy: Variants in COMT and aromatase shape how we approach testosterone, estrogen, and progesterone optimization.

Guidance from the clinic

Fishtown Medicine

A 90-minute conversation with Dr. Ash. A written plan you can actually follow.

Start your intake

"Your genes code for proteins, but your environment chooses which proteins are active. Genetics sets the predisposition, but lifestyle decides the outcome. By knowing what you are predisposed to, we can design an environment where that risk is never expressed. This is not about fear. It is about the ultimate form of clinical agency."

Actionable Steps for Genetic Agency

Equip your biology.

Download your raw data: Log into your consumer DNA account and download the raw data file today.
Upload to Ultralight: Send the file as a secure attachment in the app.
Schedule a deep-dive review: We typically need 7 to 10 days to process the data through our pathway models before a full consult.
Pair with labs: Your genetic data is most useful when paired with current ApoB, fasting insulin, hsCRP, and hormone panels.

Key Takeaways

Genetics is a blueprint, not a destiny.
We translate raw data into actionable pathways.
Genetic data informs nutrients, medications, and screening timelines.
Privacy matters: your data lives in our HIPAA-compliant, encrypted system.

Scientific References

Khera AV, et al. "Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations." Nature Genetics. 2018.
Hou L, et al. "Pharmacogenomic Testing in Clinical Practice." American Journal of Health-System Pharmacy. 2020.
Manchanda R, et al. "Cost-effectiveness of population-based BRCA1, BRCA2 mutation testing." JAMA Oncology. 2018.
Genin E, et al. "APOE and Alzheimer disease: a major gene with semi-dominant inheritance." Molecular Psychiatry. 2011.

Dr. Ash is a board-certified internal medicine physician specializing in preventive medicine and healthspan optimization at Fishtown Medicine in Philadelphia.

Fishtown Medicine | Diagnostics

2418 E York St, Philadelphia, PA 19125(267) 360-7927 hello@fishtownmedicine.comHSA/FSA Eligible

Upload Results

Frequently Asked Questions

Common Questions

A few simple choices at checkout keep your data more private. Order the kit under a pseudonym or initials rather than your full legal name, enter only your birth year instead of your full date of birth, and choose a one-time kit purchase rather than a subscription with ongoing data features. Once your raw file is downloaded, you can delete the data (and the account) from the testing company entirely; the raw file in your possession is all we need for the clinical review.

Deep-Dive Questions

Ready when you are

Start your intake

Dr. Ash reads every intake himself, and answers questions personally - usually within a few hours.

TL;DR30-second take

We do not just look for "bad genes." We look for opportunities to optimize nutrition, medication choice, screening timelines, and lifestyle around your unique biology.

What kind of genetic data can you send us?

You can send us several kinds of genetic data, and we can work with most of them:

Raw DNA data: If you have used 23andMe or Ancestry, you can download your raw .txt file and we run it through clinical-grade analysis tools.
Clinical panels: Reports from companies like Invitae or Color used for cancer screening or familial hypercholesterolemia.
Whole genome sequencing: A 30x WGS report from Nucleus or Nebula covers 100% of your DNA.
Specialized panels: Pharmacogenomic tests, MTHFR-specific reports, APOE status, and BRCA testing.

How to share: Upload files directly to your secure portal in the Ultralight app. We never email genetic data.

What is our interpretation framework?

Our interpretation framework uses pathway analysis instead of single-gene labeling. We do not crown you "the MTHFR patient" or "the APOE4 patient." We ask: where does your biology need extra support?

Metabolic pathway: Genetic tendencies toward insulin resistance, high triglycerides, or fatty liver.
Detoxification pathway: How well your body handles oxidative stress, alcohol, and environmental exposures.
Cardiovascular pathway: Markers like Lp(a) and familial hypercholesterolemia variants that standard labs often miss.
Longevity pathway: APOE status, polygenic risk scores for neurodegeneration, and protective strategies you can deploy today.
Pharmacogenomics: How fast or slow you metabolize specific drug families (CYP2D6, CYP2C19, CYP3A4).

How does genetics change your care plan?

Genetics changes your care plan by replacing generalized advice with precision action. A few real examples:

Nutrient precision: A specific MTHFR variant may push us to use methylated B-vitamins instead of standard ones.
Medication safety: CYP2D6 status changes the safe dose of antidepressants, opioids, and beta-blockers.
Screening timelines: A high polygenic risk score for breast or colon cancer can move your preventive imaging timelines up by a decade.
Cardiovascular targets: APOE4 carriers often need stricter ApoB and saturated-fat targets, since the gene amplifies risk from both.
Hormone strategy: Variants in COMT and aromatase shape how we approach testosterone, estrogen, and progesterone optimization.

Guidance from the clinic

Fishtown Medicine

A 90-minute conversation with Dr. Ash. A written plan you can actually follow.

Start your intake

Actionable Steps for Genetic Agency

Equip your biology.

Download your raw data: Log into your consumer DNA account and download the raw data file today.
Upload to Ultralight: Send the file as a secure attachment in the app.
Schedule a deep-dive review: We typically need 7 to 10 days to process the data through our pathway models before a full consult.
Pair with labs: Your genetic data is most useful when paired with current ApoB, fasting insulin, hsCRP, and hormone panels.

Key Takeaways

Genetics is a blueprint, not a destiny.
We translate raw data into actionable pathways.
Genetic data informs nutrients, medications, and screening timelines.
Privacy matters: your data lives in our HIPAA-compliant, encrypted system.

Scientific References

Khera AV, et al. "Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations." Nature Genetics. 2018.
Hou L, et al. "Pharmacogenomic Testing in Clinical Practice." American Journal of Health-System Pharmacy. 2020.
Manchanda R, et al. "Cost-effectiveness of population-based BRCA1, BRCA2 mutation testing." JAMA Oncology. 2018.
Genin E, et al. "APOE and Alzheimer disease: a major gene with semi-dominant inheritance." Molecular Psychiatry. 2011.

Dr. Ash is a board-certified internal medicine physician specializing in preventive medicine and healthspan optimization at Fishtown Medicine in Philadelphia.